Literature DB >> 23109406

Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study.

Chiadi E Ndumele1, Kunihiro Matsushita2, Brad Astor3, Salim S Virani4, Samia Mora5, Emma K Williams2, Ron C Hoogeveen4, Roger S Blumenthal6, A Richey Sharrett2, Christie M Ballantyne4, Josef Coresh7.   

Abstract

AIMS: There are conflicting guidelines regarding the measurement of apolipoproteins (apoB, apoA-1), in addition to standard lipoprotein cholesterol measures, for cardiovascular risk assessment among individuals with obesity or insulin resistance syndromes. This study aims to assess whether apolipoprotein assessments add prognostic information regarding coronary heart disease (CHD) risk beyond standard lipoprotein cholesterol measurements among individuals with obesity, diabetes, and the metabolic syndrome. METHODS AND
RESULTS: We followed 9026 participants in the Atherosclerosis Risk in Communities (ARIC) study without cardiovascular disease at baseline (visit 4, 1996-99). We compared the associations of apoB, apoA-1, and their respective lipoprotein cholesterol measures with incident CHD events among individuals with and without obesity, the metabolic syndrome, or diabetes. Over a median follow up of 10.1 years, there were 903 CHD events. Among participants with obesity, the top quintiles of apoB (HR 2.00, 95% CI 1.40-2.85 compared with the bottom quintile) and the apoB/apoA-1 ratio (HR 2.47, 95% CI 1.53-4.01) did not demonstrate stronger associations with CHD than the top quintiles of non-high-density-lipoprotein cholesterol (non-HDL-C) (HR 2.54, 95% CI 1.65-3.89) and the ratio of non-HDL-C/HDL-C (HR 4.28, 95% CI 2.29-8.03). Analogous findings were seen among patients with diabetes and the metabolic syndrome. In models adjusted for non-HDL-C and HDL-C, apoB (p = 0.94) and apoA-1 (p = 0.55) were not significantly associated with CHD events among those with obesity, in contrast to non-HDL-C and HDL-C (p = 0.02 for both).
CONCLUSIONS: Among individuals with obesity and insulin resistance syndromes, apolipoproteins did not provide prognostic information regarding CHD risk beyond that provided by non-HDL-C and HDL-C. © The European Society of Cardiology 2012.

Entities:  

Keywords:  Apolipoproteins; cholesterol; diabetes mellitus; insulin resistance; lipids; obesity

Mesh:

Substances:

Year:  2012        PMID: 23109406     DOI: 10.1177/2047487312465523

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  8 in total

1.  Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants.

Authors:  Brian T Steffen; Weihua Guan; Alan T Remaley; James H Stein; Mathew C Tattersall; Joel Kaufman; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2017-07-12       Impact factor: 4.766

Review 2.  Assessing Cardiovascular Risk and Testing in Type 2 Diabetes.

Authors:  Anum Saeed; Christie M Ballantyne
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

3.  Predictive value of serum apolipoprotein B/apolipoprotein A-I ratio in metabolic syndrome risk: a Chinese cohort study.

Authors:  Yu-Ching Chou; Jen-Chun Kuan; Chyi-Huey Bai; Tsan Yang; Wan-Yun Chou; Po-Chien Hsieh; San-Lin You; Lee-Ching Hwang; Chien-Hua Chen; Cheng-Yu Wei; Chien-An Sun
Journal:  Endocrine       Date:  2014-10-12       Impact factor: 3.633

4.  Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Brian T Steffen; Weihua Guan; Alan T Remaley; Pathmaja Paramsothy; Susan R Heckbert; Robyn L McClelland; Philip Greenland; Erin D Michos; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12-04       Impact factor: 8.311

5.  The value of the apoB/apoAΙ ratio and the non-HDL-C/HDL-C ratio in predicting carotid atherosclerosis among Chinese individuals with metabolic syndrome: a cross-sectional study.

Authors:  Guangming Qin; Jiangfeng Tu; Chenjing Zhang; Xiaoxiao Tang; Laisheng Luo; Jiaqi Wu; Lingang Liu; Wen Lu; Lisha Tao; Shengrong Shen; Undurti N Das; Wensheng Pan
Journal:  Lipids Health Dis       Date:  2015-04-09       Impact factor: 3.876

Review 6.  Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy.

Authors:  Olov Wiklund; Carlo Pirazzi; Stefano Romeo
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

7.  Importance of lipid ratios for predicting intracranial atherosclerotic stenosis.

Authors:  Wen-Song Yang; Rui Li; Yi-Qing Shen; Xing-Chen Wang; Qing-Jun Liu; Hai-Yang Wang; Qi Li; Guo-En Yao; Peng Xie
Journal:  Lipids Health Dis       Date:  2020-07-04       Impact factor: 3.876

8.  Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study.

Authors:  Liang Gao; Yaju Zhang; Xingmin Wang; Hongli Dong
Journal:  BMC Endocr Disord       Date:  2021-04-01       Impact factor: 2.763

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.